bluuebunny/crossref_metadata_2025_split huggingface dataset:
Evaluating the impact of internal control systems on organizational effectiveness
Authors: Otoo Frank Nana Kweku , Kaur Manpreet , Rather Nissar Ahmed 
Published: September 2023

PurposeInternal control systems are critical to an organization's efficiency and promotes the adherence to norms and rules. The purpose of this study is to evaluate the impact of internal control systems on banking industry effectiveness.Design/methodology/approachData were collected from 15 commercial and 20 rural banks. The hypothesized relationships were supported by the data. A structural equation modeling was applied in testing the conceptual model and hypothesis. Confirmatory factor analysis was conducted to establish validity and reliability of the dimensions.FindingsThe results show that organizational effectiveness was significantly impacted by three dimensions of internal control systems: control activities, control environments and risk assessment. However, the impact of monitoring of control on organizational effectiveness was not significant. The results also show a nonsignificant impact of information and communication on organizational effectiveness.Research limitations/implicationsSince the current study concentrated on the banking sector with its distinct characteristics, the generalizability of the conclusions may be limited.Practical implicationsThe study's findings may aid decision-makers and stakeholders in the adoption, designing and implementation of proactive internal control system to enhance operational efficiency, effectiveness and competitive advantage.Originality/valueThe study advances the literature by empirically evidencing that internal control systems impact organizational effectiveness.
How perceived corporate social responsibility affects consumer citizenship behavior? Investigating the mediating roles of perceived employee behavior and consumer company identification
Authors: Utkarsh  , Singh Harmanjit 
Published: September 2023

PurposeThe purpose of this study is to understand the detailed mechanism through which consumer citizenship behavior gets affected by corporate social responsibility through perceived employee behavior and consumer company identification.Design/methodology/approachThe study subjects data from cross-sectional survey of 405 retail store consumers to structural equation modeling.FindingsThe results indicate that consumer company identification plays a very crucial role as it mediates the effect of corporate social responsibility and employee behavior on consumer citizenship behavior. In addition, the results also indicate that corporate social responsibility perceptions lead to positive employee behavior.Originality/valueThe study contributes to the literature on consumer citizenship behavior by identifying and filling up two major gaps in the retail outlets' context: (1) the limited empirical investigation of antecedents of consumer citizenship behavior up to third-level (i.e. antecedent of antecedent of antecedent) (2) the lack of clarity on the exact mechanism through which perceived corporate social responsibility influences consumer citizenship behavior, and the role of consumer company identification as a mediator in this relationship.
Building Parallel Supply Chains: How the Manufacturing Location Decision Influences Supply Chain Ambidexterity
Authors: Moradlou Hamid , Boffelli Albachiara , Mwesiumo Deodat Edward , Benstead Amy , Roscoe Samuel , Khayyam Sanaa 
Published: September 2023

AbstractThe purpose of this paper is to examine how managers can develop ‘parallel’ supply chains to overcome the efficiency/flexibility trade‐offs of offshored versus reshored/nearshored production. Primary evidence is gathered from 22 field interviews with eight companies from multiple countries, all operating in the textile and apparel industry. The interview data is triangulated using a cross‐industry focus group with 28 participants and secondary sources including company annual reports and website information. The study contributes to organizational ambidexterity theory by identifying how companies embed structural ambidexterity in their supply chains, and in so doing create ‘parallel supply chains’. Our findings show that companies partition their production in terms of width (meaning that specific product lines were relocated) and depth (meaning that specific production activities were relocated). Companies then use a mix of offshored production facilities to manufacture low‐margin, long‐lead‐time products as well as reshored/nearshored production facilities to make high‐margin, quick‐response items. The ability to swap production volumes between parallel supply chains enables supply chain ambidexterity, which in turn allows companies to exploit efficiency and flexibility benefits simultaneously. Managers are provided with an empirically informed, step‐by‐step framework for developing structural ambidexterity and building parallel supply chains.
Addressing adverse synergies between chemical and biological pollutants at schools—The ‘SynAir‐G’ hypothesis
Authors: Papadopoulos Nikolaos G. , Akdis Cezmi , Akdis Mubeccel , Damialis Athanasios , Esposito Giuseppina , Fergadiotou Ioana , Goroncy Christian , Guitton Pierre , Gotua Maia , Erotokritou Kleanthis , Jartti Tuomas , Murray Clare , Nenes Athanasios , Nikoletseas Sotirios , Finotto Susetta , Pandis Spyros N. , Ramiconi Valeria , Simpson Angela , Soudunsaari Aki , Stårbröst Anna , Staiano Maria , Varriale Antonio , Xepapadaki Paraskevi , Zuberbier Torsten , Annesi‐Maesano Isabella ,   The SynAir‐G Consortium
Published: September 2023

AbstractWhile the number and types of indoor air pollutants is rising, much is suspected but little is known about the impact of their potentially synergistic interactions, upon human health. Gases, particulate matter, organic compounds but also allergens and viruses, fall within the ‘pollutant’ definition. Distinct populations, such as children and allergy and asthma sufferers are highly susceptible, while a low socioeconomic background is a further susceptibility factor; however, no specific guidance is available. We spend most of our time indoors; for children, the school environment is of paramount importance and potentially amenable to intervention. The interactions between some pollutant classes have been studied. However, a lot is missing with respect to understanding interactions between specific pollutants of different classes in terms of concentrations, timing and sequence, to improve targeting and upgrade standards. SynAir‐G is a European Commission‐funded project aiming to reveal and quantify synergistic interactions between different pollutants affecting health, from mechanisms to real life, focusing on the school setting. It will develop a comprehensive and responsive multipollutant monitoring system, advance environmentally friendly interventions, and disseminate the generated knowledge to relevant stakeholders in accessible and actionable formats. The aim of this article it to put forward the SynAir‐G hypothesis, and describe its background and objectives.
Individual and contextual predictors of young Ukrainian adults' subjective well‐being during the Russian–Ukrainian war
Authors: Pavlova Iuliia , Krauss Steven , McGrath Breeda , Cehajic‐Clancy Sabina , Bodnar Ivanna , Petrytsa Petro , Synytsya Tetiana , Zhara Hanna 
Published: September 2023

AbstractThe Russian invasion of Ukraine is accompanied by horrific losses among civilians. This study investigates various individual (hope, optimism, resilience, post‐traumatic growth, and coping strategies) and contextual predictors (experience of life under occupation, actively hostile home environment, and frequent moves) of subjective well‐being among the youth living in Ukraine. A total sample of 593 students from several universities participated in the study using surveys that contained questions about sociodemographic characteristics, life satisfaction, hope, optimism, personal post‐traumatic growth, resilience, and coping strategies. Data were analyzed using JAMOVI software. The level of dissatisfaction with their own lives was 34.7%; most of the respondents had a higher incidence of minimal/mild hopelessness (88.7%) and high/moderate level of optimism (60.9%). The majority of participants had moderate and high levels of post‐traumatic growth (51.9% and 6.7%, respectively) and resilience (46.0% and 14.5%, respectively). Optimism, hope, resilience, post‐traumatic growth, using emotional support, and life in occupation predicted life satisfaction among the study sample.
Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis
Authors: Buch Stephan , Sharma Aneesh , Ryan Eleanor , Datz Christian , Griffiths William J. H. , Way Michael , Buckley Thomas W. M. , Ryan John D. , Stewart Stephen , Wright Callum , Dongiovanni Paola , Fracanzani Anna , Zwerina Jochen , Merle Uta , Weiss Karl Heinz , Aigner Elmar , Krones Elisabeth , Dejaco Christian , Fischer Janett , Berg Thomas , Valenti Luca , Zoller Heinz , McQuillin Andrew , Hampe Jochen , Stickel Felix , Morgan Marsha Y. 
Published: September 2023

SummaryBackgroundCirrhosis develops in <10% of individuals homozygous for the C282Y variant in the homeostatic iron regulator (HFE) gene. Carriage of PCSK7:rs236918 is associated with an increased risk of cirrhosis in this population.AimTo determine if genetic variants significantly associated with the risk of alcohol‐ and NAFLD‐related cirrhosis also modulate the cirrhosis risk in C282Y homozygotes.MethodsVariants in PCSK7, PNPLA3, TM6SF2, MBOAT7 and HSD17B13 were genotyped in 1319 C282Y homozygotes, from six European countries, of whom 171 (13.0%) had cirrhosis. Genotypic and allelic associations with the risk for developing cirrhosis were assessed, adjusting for age and sex. Fixed effects meta‐analyses of the adjusted summary data for each country were performed. Post hoc association testing was undertaken in the 131 (76.6%) cases and 299 (26.0%) controls with available liver histology.ResultsSignificant associations were observed between PCSK7:rs236918 (OR = 1.52 [95% CI 1.06‐2.19]; P = 0.022; I2 = 0%); PNPLA3:rs738409 (OR = 1.60 [95% CI 1.22‐2.11]; P = 7.37 × 10−4; I2 = 45.5%) and TM6SF2:rs58542926 (OR = 1.94 [95% CI 1.28‐2.95]; P = 1.86 × 10−3; I2 = 0%) and the cirrhosis risk in C282Y homozygotes. These findings remained significant in the subpopulation with available liver histology. The population‐attributable fractions were 5.6% for PCSK7:rs236918, 13.8% for PNPLA3:rs738409, 6.5% for TM6SF2:rs58542926 and 24.0% for carriage of all three variants combined.ConclusionsThe risk of cirrhosis associated with carriage of PCSK7:rs236918 was confirmed in this much larger population of C282Y homozygotes. In addition, PNPLA3:rs738409 and TM6SF2:rs58542926 were established as significant additional risk factors. More detailed genetic testing of C282Y homozygotes would allow risk stratification and help guide future management.
Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
Authors: Tseng Tai‐Chung , Liu Chun‐Jen , Yang Wan‐Ting , Hsu Chen‐Yang , Hong Chun‐Ming , Su Tung‐Hung , Tsai Cheng‐Hsueh , Chen Chi‐Ling , Yang Hung‐Chih , Liu Chen‐Hua , Chen Hsiu‐Hsi , Chen Pei‐Jer , Kao Jia‐Horng 
Published: September 2023

SummaryBackgroundPatients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication.AimTo explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000‐19 999 IU/mL) due to their moderate risk of disease progression.MethodsA total of 1673 treatment‐naïve, non‐cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load.ResultsOf the 1673 patients, 104 developed cirrhosis after a mean follow‐up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis‐related complications, and liver‐related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61‐6.47). The risk stratification remained significant when exploring other pre‐cirrhosis endpoints, including HBeAg‐negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow‐up.ConclusionsIn HBeAg‐negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low‐risk group for disease progression.
Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication
Authors: Leung Wai K. , Cheung Ka Shing , Li Bofei , Law Simon Y. K. , Lui Thomas K. L. 
Published: September 2023

SummaryBackgroundThe risk of gastric cancer after Helicobacter pylori (H. pylori) eradication remains unknown.AimTo evaluate the performances of seven different machine learning models in predicting gastric cancer risk after H. pylori eradication.MethodsWe identified H. pylori‐infected patients who had received clarithromycin‐based triple therapy between 2003 and 2014 in Hong Kong. Patients were divided into training (n = 64 238) and validation sets (n = 25 330), according to period of eradication therapy. The data were used to construct seven machine learning models to predict risk of gastric cancer development within 5 years after H. pylori eradication. A total of 26 clinical variables were input into these models. The performances were measured by the area under receiver operating characteristic curve (AUC) analysis.ResultsDuring a mean follow‐up of 4.7 years, 0.21% of H. pylori‐eradicated patients developed gastric cancer. Of the seven machine learning models, extreme gradient boosting (XGBoost) had the best performance in predicting cancer development (AUC 0.97, 95%CI 0.96‐0.98), and was superior to conventional logistic regression (AUC 0.90, 95% CI 0.84‐0.92). With the XGBoost model, the number of patients considered at high risk of gastric cancer was 6.6%, with miss rate of 1.9%. Patient age, presence of intestinal metaplasia, and gastric ulcer were the heavily weighted factors used by the XGBoost.ConclusionBased on simple baseline patient information, machine learning model can accurately predict the risk of post‐eradication gastric cancer. This model could substantially reduce the number of patients who require endoscopic surveillance.
Editorial: machine learning models for gastric cancer risk prediction
Authors: Spaander Manon C. W. , Kuipers Ernst J. 
Published: September 2023

LINKED CONTENTThis article is linked to Leung et al and Leung & Lui papers. To view these articles, visit https://doi.org/10.1111/apt.16272 and https://doi.org/10.1111/apt.16319
Editorial: stratifying risk of adverse outcomes in cirrhosis—the Hepquant SHUNT test. Authors' reply
Authors: Asrani Sumeet K. , Everson Gregory T. 
Published: September 2023

LINKED CONTENTThis article is linked to Fallahzadeh et al and Maan & Sonneveld papers. To view these articles, visithttps://doi.org/10.1111/apt.16283andhttps://doi.org/10.1111/apt.16299
Letter: tenofovir may be superior to entecavir for treatment‐naïve chronic hepatitis B patients
Authors: Wang Ji‐Gan , Chen Rui , Wang Li‐Chuan 
Published: September 2023

LINKED CONTENTThis article is linked to Pol et al papers. To view these articles, visit https://doi.org/10.1111/apt.16197 and https://doi.org/10.1111/apt.16340
Early detection of anti‐drug antibodies during initiation of anti‐tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease
Authors: Tournier Quentin , Paul Stephane , Williet Nicolas , Berger Anne‐Emmanuelle , Veyrard Pauline , Boschetti Gilles , Le Roy Bertrand , Killian Martin , Phelip Jean Marc , Flourie Bernard , Nancey Stephane , Roblin Xavier 
Published: September 2023

SummaryBackgroundAnti‐drug antibodies develop mostly during the induction therapy with anti‐tumour necrosis factor (TNF) drugs and can be revealed by means of a drug‐tolerant assay.AimTo investigate whether the early detection of anti‐drug antibodies during the induction therapy was predictive of treatment discontinuation.MethodsIn a prospective study, consecutive patients with inflammatory bowel disease (IBD), who should start an anti‐TNF, were enrolled and followed regularly during 24 months or less in case of non‐ or loss of response (LOR) or adverse events requiring treatment discontinuation. Anti‐TNF levels and anti‐drug antibodies were measured at week 2 for adalimumab (ADA) and weeks 2 and 6 for infliximab (IFX) using a drug‐tolerant assay.ResultsOne hundred and eight patients were enrolled (54 under ADA). At week 2, antibodies to ADA and to IFX were detected in 76% and 67% of patients. Time to treatment discontinuation was significantly shorter (P < 0.001) in patients with antibodies to ADA ≥2.0 µg/mL‐eq (6.0 vs 24 months, HR = 18.51, 95% CI [4.35‐78.71]) or with antibodies to IFX ≥4.0 µg/mL‐eq (5.5 vs >24 months, HR = 13.89, 95% CI [4.08‐47.31]) at week 2 compared to patients without positive antibodies. Antibodies to ADA and to IFX were predictive of treatment failure within 24 months with a sensitivity of 79% and 62%, and specificities and positive predictive values of 100%. In multivariate analysis, antibodies to ADA or to IFX at week 2 were the only factors associated with treatment discontinuation.ConclusionsThe prevalence of antibodies to anti‐TNF is high when detected early using a drug‐tolerant assay, and their appearance predicts further treatment discontinuation.
Editorial: bariatric surgery to reduce the risk of liver cancer—authors' reply
Authors: Ramai Daryl , Facciorusso Antonio 
Published: September 2023

LINKED CONTENTThis article is linked to Ramai et al and Pirola & Sookoian papers. To view these articles, visit https://doi.org/10.1111/apt.16335 and https://doi.org/10.1111/apt.16357
Medication use and microscopic colitis: a multicentre retrospective cohort study
Authors: Zylberberg Haley M. , Kamboj Amrit K. , De Cuir Nicole , Lane Conor M. , Khanna Sahil , Pardi Darrell S. , Lebwohl Benjamin 
Published: September 2023

SummaryBackgroundMedication use has been implicated in the development of microscopic colitis (MC). However, studies have demonstrated inconsistent findings and there exist variations in design.AimTo measure the association between medication use and MC.MethodsPatients who underwent a colonoscopy over a 10‐year period at two academic medical centres (Columbia University Medical Centre and Mayo Clinic) were identified. Cases were patients with biopsy‐proven MC and controls were patients who underwent colonoscopy for evaluation of diarrhoea with biopsies negative for MC. Cases were matched by age, gender and calendar period with up to two controls. Demographics, medication use, smoking history and coeliac disease status were collected. Conditional logistic regression was used with and without adjustment for smoking.ResultsA total of 344 patients with MC were matched to 668 controls. After adjusting for smoking, there was an inverse association between MC and use of proton pump inhibitors (PPIs) (OR 0.64; 95% CI 0.47‐0.87), H2 blockers (OR 0.46; 95% CI 0.24‐0.88) and oral diabetes medications (OR 0.47; 95% CI 0.27‐0.81). There was a positive association with nonsteroidal anti‐inflammatory drug (NSAID) use and MC (OR 1.63; 95% CI 1.12‐2.38).ConclusionsNSAID use was associated with MC, while use of PPIs, H2 blockers and oral diabetes medications were inversely related to MC. Our use of a control group with diarrhoea, as opposed to healthy controls, may have contributed to these inverse associations. Future studies of drug‐induced microscopic colitis should include control groups with diarrhoea, and not only healthy controls.
Considerations on implementation of the newest treatment for symptomatic uterine fibroids: Oral GnRH antagonists
Authors: de Lange Maria E. , Semmler Annika , Clark T. Justin , Mol Ben Willem J. , Bet Pierre M. , Huirne Judith A. F. , Hehenkamp Wouter J. K. 
Published: September 2023

AbstractNovel gonadotrophin releasing hormone (GnRH) antagonist treatments have recently been developed in combination with hormonal add‐back therapy, as an oral treatment option for women suffering from uterine fibroids. Registration trials assessing the GnRH antagonist combination preparations with relugolix, elagolix and linzagolix have assessed treatment efficacy for fibroid‐related heavy menstrual blood loss in comparison to placebo. Marketing authorization has been granted by several agencies including those in Europe, the United Kingdom and the United States. While the registration trials report a robust effect on the reduction of heavy menstrual blood loss and improvement in quality of life scores, reticence is advised before widespread prescription. In this review, we demonstrate limitations in the trial data, namely a lack of generalizability due to the restricted study population, the lack of transparency in the distribution of disease‐level characteristics limiting the predictability of treatment success in the real‐world diverse population, and the absence of any comparison to current alternative treatment methods. Importantly, no clinically meaningful volume reductions were found with GnRH antagonist combination preparations, and long‐term safety data, particularly concerning modest but stable bone mineral density decline, need further addressing. Symptoms related to uterine fibroids adversely affect many women's quality of life and effective medical treatments are lacking. However, despite the urgent need for conservative treatments, it is vitally important that novel drugs, like combination oral GnRH antagonists, undergo sufficiently rigorous evaluation of safety, effectiveness and cost‐effectiveness in a representative population and are compared with alternative treatment methods before introduction into mainstream clinical practice.